Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC

Over the last decade, the immune checkpoint blockade targeting the programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis has improved progression-free and overall survival of advanced non-small cell lung cancer (NSCLC) patients. PD-L1 tumor expression, along with tumor mutational...

Descripción completa

Detalles Bibliográficos
Autores principales: Kloten, Vera, Lampignano, Rita, Krahn, Thomas, Schlange, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721635/
https://www.ncbi.nlm.nih.gov/pubmed/31374957
http://dx.doi.org/10.3390/cells8080809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721635/
https://www.ncbi.nlm.nih.gov/pubmed/31374957
http://dx.doi.org/10.3390/cells8080809

Ejemplares similares